Ascendis Pharma A/S (ASND) has disclosed a new risk, in the Share Price & Shareholder Rights category.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Ascendis Pharma A/S faces a potential risk of dilution due to the exercise or conversion of approximately 12.9 million shares linked to outstanding warrants, RSUs, PSUs, and convertible notes. These shares, eligible for public sale as of December 31, 2024, could be exercised or converted at prices below the market value of the ADSs, leading to a decrease in the value of existing ADSs. The settlement of RSUs and PSUs into additional ADSs could further impact the share value, posing a significant financial risk to current shareholders. Investors should consider the implications of these potential dilutions on their holdings and the overall market perception of the company’s value.
The average ASND stock price target is $197.43, implying 38.56% upside potential.
To learn more about Ascendis Pharma A/S’ risk factors, click here.
